Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

Journal of Hepatology

Volumn 52, Issue 1, 2010, Pages 88-95

  Chen, Kuen Feng ^a   Yu, Hui Chuan ^a   Liu, Tsung Hao ^a   Lee, Shoei Sheng ^b   Chen, Pei Jer ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Akt; Apoptosis; HCC; Molecular targeted therapy; PP2A; Proteasome inhibitor; Sorafenib

Indexed keywords

1,9 DIDEOXYFORSKOLIN; BORTEZOMIB; OKADAIC ACID; PROTEIN KINASE B; SORAFENIB;

APOPTOSIS; ARTICLE; DRUG EFFECT; DRUG EFFICACY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84984585952     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.011     Document Type: Article

References (27)

1. Verslype C., Cutsem E.V., Dicato M., Arber N., Berlin J.D., Cunningham D., et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20 Suppl. 7 (2009) vii1-vii6
2. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
3. Voorhees P.M., and Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46 (2006) 189-213
4. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., and San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9 (2008) 1157-1165
5. Chen K.F., Yeh P.Y., Yeh K.H., Lu Y.S., Huang S.Y., and Cheng A.L. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68 (2008) 6698-6707
6. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (2006) 11851-11858
7. Kane R.C., Farrell A.T., Saber H., Tang S., Williams G., Jee J.M., Liang C., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12 (2006) 7271-7278
8. Ding Q., Huo L., Yang J.Y., Xia W., Wei Y., Liao Y., Chang C.J., et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 68 (2008) 6109-6117
9. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282 (2007) 29831-29846
10. Rosato R.R., Almenara J.A., Coe S., and Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67 (2007) 9490-9500
11. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12 (2007) 66-80
12. Dasmahapatra G., Yerram N., Dai Y., Dent P., and Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 13 (2007) 4280-4290
13. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., Fesik S.W., et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26 (2007) 3972-3979
14. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97 (2000) 10832-10837
15. Arroyo J.D., and Hahn W.C. Involvement of PP2A in viral and cellular transformation. Oncogene 24 (2005) 7746-7755
16. Ugi S., Imamura T., Maegawa H., Egawa K., Yoshizaki T., Shi K., Obata T., et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24 (2004) 8778-8789
17. Yamada T., Katagiri H., Asano T., Inukai K., Tsuru M., Kodama T., Kikuchi M., et al. 3-phosphoinositide-dependent protein kinase 1, an Akt1 kinase, is involved in dephosphorylation of Thr-308 of Akt1 in Chinese hamster ovary cells. J Biol Chem 276 (2001) 5339-5345
18. Rocher G., Letourneux C., Lenormand P., and Porteu F. Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 282 (2007) 5468-5477
19. Janssens V., and Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353 (2001) 417-439
20. Kulp S.K., Yang Y.T., Hung C.C., Chen K.F., Lai J.P., Tseng P.H., Fowble J.W., et al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64 (2004) 1444-1451
21. Liu Q., Zhao X., Frissora F., Ma Y., Santhanam R., Jarjoura D., Lehman A., et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111 (2008) 275-284
22. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
23. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
24. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., Liu S., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117 (2007) 2408-2421
25. Matsuoka Y., Nagahara Y., Ikekita M., and Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 138 (2003) 1303-1312
26. Yu C., Friday B.B., Lai J.P., Yang L., Sarkaria J., Kay N.E., Carter C.A., et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5 (2006) 2378-2387
27. Wang Z., Zhou J., Fan J., Qiu S.J., Yu Y., Huang X.W., et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14 (2008) 5124-5130